Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response-Reference-Cited by-同舟云学术

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

Published:2007-09-14 Issue:1 Volume:5 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Rüttinger Dominik,van den Engel Natasja K,Winter Hauke,Schlemmer Marcus,Pohla Heike,Grützner Stefanie,Wagner Beate,Schendel Dolores J,Fox Bernard A,Jauch K-W,Hatz Rudolf A

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1479-5876-5-43.pdf

Reference29 articles.

1. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993, 90: 3539-3543. 10.1073/pnas.90.8.3539.

2. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003, 21: 624-630. 10.1200/JCO.2003.03.091.

3. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, Hamilton S, Borellini S, Lin A, Morali S, Hege K: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004, 96: 326-331.

4. Smyth M, Godfrey D, Trapani J: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001, 2: 293-299. 10.1038/86297.

5. Levitsky HI: Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance. Cancer J. 2000, 6: S281-290.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new frontier in cancer therapy: The intersection of cancer vaccines and metabolomics;Metabolomics for Personalized Vaccinology;2024

2. Cancer Vaccines in the Immunotherapy Era: Promise and Potential;Vaccines;2023-11-29

3. Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines;Pharmaceutics;2023-02-16

4. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma;Oncology Research;2023

5. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions;International Journal of Molecular Sciences;2022-04-15